ImageneBio (IMA) Liabilities and Shareholders Equity (2020 - 2025)

ImageneBio has disclosed Liabilities and Shareholders Equity across 6 years of filings, most recently posting $153.0 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $153.0 million, up 860.78% year-over-year; the trailing twelve-month figure through Dec 2025 was $570.9 million (up 15.28% YoY), and the FY2025 annual result was $153.0 million, up 860.78% from the prior year.
• Liabilities and Shareholders Equity came in at $153.0 million for Q4 2025 at ImageneBio, down from $160.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $293.7 million in Q1 2021 to a low of $15.9 million in Q4 2024.
• The 5-year median for Liabilities and Shareholders Equity is $172.5 million (2022), against an average of $184.1 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 91.71% in 2024 and jumped 860.78% in 2025, its largest moves.
• ImageneBio's Liabilities and Shareholders Equity stood at $247.9 million in 2021, then slumped by 30.51% to $172.3 million in 2022, then climbed by 11.51% to $192.1 million in 2023, then slumped by 91.71% to $15.9 million in 2024, then surged by 860.78% to $153.0 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $153.0 million (Q4 2025), $160.9 million (Q3 2025), and $126.2 million (Q2 2025), per Business Quant data.